Dr. Reddy’s Laboratories announces the launch of Bivalirudin for Injection in the U.S. Market


Dr. Reddy’s Laboratories Ltd. announced today that it has launched Bivalirudin for Injection, 250 mg/vial, a therapeutic equivalent generic version of Angiomax®(Bivalirudin) for Injection, approved by the U.S. Food and Drug Administration (USFDA).


The Angiomax® brand and generic had U.S. sales of approximately $198 million MAT for the most recent twelve months ending in March 2017 according to IMS Health*.

Dr. Reddy’s Bivalirudin Injection, 250 mg/vial, are available in packages of 10 single-dose vials.

Angiomax® is a registered trademark of The Medicines Company.

Don't be shellfish...Share on Facebook0Share on Google+0Share on LinkedIn0Share on StumbleUpon0Pin on Pinterest0Tweet about this on Twitter0
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Most Popular

To Top